Healthcare industry

Assay to support the diagnosis of autoimmune diseases - 22/06/2022

Tracking down pathogenic immune complexes

Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.

Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

Intelligent Diagnostics - 09/02/2022

AI for added value in digital melanoma diagnostics

Intelligent Diagnostics is an interdisciplinary project that brings together the latest technologies and research institutes to better support doctors in diagnosing skin cancer through innovative imaging and artificial intelligence.

microRNA as a prognostic biomarker - 13/01/2022

Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.

At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

Parkinson's disease is characterised by a slow, progressive loss of nerve cells in certain brain areas. The disease is still incurable and the exact causes are unclear. The dopamine deficiency in the brain can only be controlled to some extent in the initial phase of the disease. Basic research is being conducted in an attempt to unravel the mystery of Parkinson's disease.

After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.

As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

Microfluidic systems - 18/11/2021

Dermagnostix develops molecular diagnostic tests for skin diseases

Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023. The start-up is already working on two other dermatological tests. Centrifugal microfluidics is the name of the technology on which the tests are based.

A team of engineers and biotechnologists at the University of Freiburg has for the first time shown in mammals that the concentration of antibiotics in the body can be determined using breath samples. The breath measurements also corresponded to the antibiotic concentrations in the blood. The team’s biosensor – a multiplex chip – will in future enable personalized dosing of medicines against infectious diseases on-site.

On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.

The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a diagnosis is made. In a current study, researchers from the German Cancer Research Center and the National Center for Tumor Diseases (NCT) Heidelberg show that miRNA profiles provide greater predictive accuracy than genetic or lifestyle-based risk…

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

Article - 17/03/2021

Epigenetic switches in bacteria as biosensors

The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…

Article - 17/02/2021

Whole blood model enables development of early warning system for sepsis

Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

Article - 14/01/2021

Newly discovered RNA as growth driver in liver cancer

Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

Infection control - 07/01/2021

Gene accordions as potential markers for pathogenic properties

Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease.

Dr. André Martins from the Department of Radiology at the Tübingen University Hospitals is one of this year's recipients of the Alexander von Humboldt Foundation's Sofja Kovalevskaja Award.

EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.

New edition - 24/05/2019

Tumour metastasis

Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.